Related Experiment Video
Updated: Jun 22, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells
Daméhan Tchelougou1, Nicolas Malaquin1, Guillaume B Cardin1
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du Cancer de Montréal, Montreal, QC, Canada.
Abstract:
Malignant Melanoma that resists immunotherapy remains the deadliest form of skin cancer owing to poor clinically lasting responses. Alternative like genotoxic or targeted chemotherapy trigger various cancer cell fates after treatment including cell death and senescence. Senescent cells can be eliminated using senolytic drugs and we hypothesize that the targeted elimination of therapy-induced senescent melanoma cells could complement both conventional and immunotherapies. We utilized a panel of cells representing diverse mutational background relevant to melanoma and found that they developed distinct senescent phenotypes in response to treatment. A genotoxic combination therapy of carboplatin-paclitaxel or irradiation triggered a mixed response of cell death and senescence, irrespective of BRAF mutation profiles. DNA damage-induced senescent melanoma cells exhibited morphological changes, residual DNA damage, and increased senescence-associated secretory phenotype (SASP). In contrast, dual targeted inhibition of Braf and Mek triggered a different mixed cell fate response including senescent-like and persister cells. While persister cells could reproliferate, senescent-like cells were stably arrested, but without detectable DNA damage and senescence-associated secretory phenotype. To assess the sensitivity to senolytics we employed a novel real-time imaging-based death assay and observed that Bcl2/Bcl-XL inhibitors and piperlongumine were effective in promoting death of carboplatin-paclitaxel and irradiation-induced senescent melanoma cells, while the mixed persister cells and senescent-like cells resulting from Braf-Mek inhibition remained unresponsive. Interestingly, a direct synergy between Bcl2/Bcl-XL inhibitors and Braf-Mek inhibitors was observed when used out of the context of senescence. Overall, we highlight diverse hallmarks of melanoma senescent states and provide evidence of context-dependent senotherapeutics that could reduce treatment resistance while also discussing the limitations of this strategy in human melanoma cells.
Insights
Targeted elimination of therapy-induced senescent melanoma cells using senolytics shows promise against treatment resistance. However, senolytic drugs are ineffective against senescent-like cells induced by targeted BRAF/MEK inhibition.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Malignant melanoma resistant to immunotherapy presents a significant clinical challenge due to limited durable responses.
- Conventional and targeted therapies induce diverse cancer cell fates, including senescence, which can contribute to treatment resistance.
- Senescent cells, characterized by stable cell cycle arrest, can be targeted by senolytic drugs, offering a potential therapeutic strategy.
Purpose of the Study:
- To investigate the distinct phenotypes of therapy-induced senescent melanoma cells.
- To evaluate the efficacy of senolytic drugs against different types of melanoma senescence.
- To explore the potential of senotherapeutics to overcome treatment resistance in melanoma.
Main Methods:
- Utilized a panel of melanoma cell lines with diverse mutational backgrounds.
- Induced senescence and other cell fates using genotoxic (carboplatin-paclitaxel, irradiation) and targeted (BRAF/MEK inhibition) therapies.
- Assessed senescent phenotypes, including morphology, DNA damage, and senescence-associated secretory phenotype (SASP).
- Employed a real-time imaging-based death assay to evaluate senolytic drug sensitivity.
Main Results:
- Genotoxic therapies induced DNA damage-associated senescence with SASP.
- Targeted BRAF/MEK inhibition resulted in senescent-like cells and persister cells, lacking DNA damage and SASP.
- Senolytic drugs (Bcl2/Bcl-XL inhibitors, piperlongumine) effectively eliminated genotoxic therapy-induced senescent cells.
- Senescent-like and persister cells from BRAF/MEK inhibition were unresponsive to senolytics.
- Direct synergy was observed between Bcl2/Bcl-XL inhibitors and BRAF/MEK inhibitors outside the senescence context.
Conclusions:
- Melanoma cells exhibit diverse senescent states depending on the inducing therapy.
- Context-dependent senotherapeutics are crucial for targeting specific senescent phenotypes.
- Senolytics are effective against DNA damage-induced senescence but not senescent-like cells from targeted therapy.
- Further research is needed to address limitations and optimize senotherapeutic strategies for melanoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy